<DOC>
	<DOCNO>NCT01481194</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety combination treatment doxorubicin , cyclophosphamide , bortezomib , dexamethasone , lenalidomide newly diagnose multiple myeloma patient .</brief_summary>
	<brief_title>ACVDL Treatment Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Male female subject ≥ 18 year time signing informed consent . 2 . Subject diagnose symptomatic multiple myeloma base International Myeloma Working Group Diagnostic Criteria ( Kyle 2009 ) : Monoclonal plasma cell bone marrow ≥ 10 % and/or presence biopsyproven plasmacytoma . Monoclonal protein present serum and/or urine . If monoclonal protein detect ( nonsecretory disease ) , ≥ 30 % monoclonal bone marrow plasma cell and/or biopsyproven plasmacytoma require . Myelomarelated organ dysfunction 3 . The myeloma disease burden must measurable least one follow criterion ( Durie et al . 2006 ) : Serum Mprotein ≥ 10 g/l Urine Mprotein ≥ 200 mg/24 h Involved FLC ≥ 100 mg/l provide serum FLC ratio abnormal Bone marrow plasma cell &gt; 30 % 4 . Subject Karnofsky performance status ≥ 60 . 5 . Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . 6 . Subject willing able comply protocol judge investigator . 1 . Any prior systemic therapy multiple myeloma . 2 . Other therapy biologic therapy chemotherapy le 3 month prior screen . 3 . Any prior treatment doxorubicin anthracycline . 4 . Concurrent recent ( less 2 week prior Screening ) radiotherapy surgery . 5 . Prior glucocorticoid treatment multiple myeloma exceed dexamethasone 20mg/day maximum 7 day . Topical glucocorticosteroid therapy treat nonmalignant comorbid disorder permit . 6 . More equal grade 2 peripheral neuropathy accord NCICTC criterion clinical examination within 14 day enrolment ( Day 1 Cycle 1 ) . 7 . Evidence mucosal internal bleeding and/or platelet count &lt; 50 x 10^9/l . Platelet transfusion may use meet PLT eligibility criterion . 8 . Absolute neutrophil count ( ANC ) &lt; 1 x 10^9/l . Growth factor may use meet ANC eligibility criterion . 9 . Hemoglobin &lt; 5.0 mmol/l . The subject may include correction hemoglobin level transfusion treatment erythropoietin . 10 . Alanine aminotransferase ( ALAT ) &gt; 2 x ULN . 11 . Myocardial infarction within 6 month prior enrolment New York Heart Association ( NYHA ) Class IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen document investigator medically relevant . 12 . Clinically relevant active infection serious comorbid medical condition , chronic obstructive chronic restrictive pulmonary disease , cirrhosis . 13 . Any condition , include laboratory abnormality , opinion Investigator place subject unacceptable risk he/she participate study . 14 . Prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , situ breast cancer , situ prostate cancer subject diseasefree least 3 year . 15 . Female subject pregnant breastfeeding . The first serum pregnancy test do within 1014 day prior study treatment start repeat serum pregnancy test do within 24 hour prior start study treatment . 16 . Female subject childbearing potential ( biologically capable become pregnant ) men partner childbearing potential , unwilling unable use effective mean contraception . The mean contraception must TWO acceptable method birth control , one highly effective method ( hormonal contraceptive pill , injection implant , tubal ligation , partner 's vasectomy ) one additional effective method ( condom , diaphragm , cervical cap ) AT THE SAME TIME , least 28 day start ACVDL least 28 day last dose ACVDL . 17 . Serious medical psychiatric illness likely interfere participation clinical study . 18 . Uncontrolled diabetes mellitus discretion investigator . 19 . Hypersensitivity and/or contraindication one Investigational Medicinal Products ( IMP ) , acyclovir similar antiviral drug . 20 . POEMS syndrome ( plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein ( Mprotein ) skin change ) . 21 . Known HIV infection . 22 . Known active hepatitis B C viral infection . 23 . Known intolerance steroid therapy . 24 . Current recent ( within 30 day prior Screening ) treatment another investigational drug . 25 . Unable comply administration study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
</DOC>